Annals of Surgical Oncology

, Volume 14, Issue 11, pp 3195–3201 | Cite as

Recurrence and Prognostic Factors of Ampullary Carcinoma after Radical Resection: Comparison with Distal Extrahepatic Cholangiocarcinoma

  • Sang Myung Woo
  • Ji Kon Ryu
  • Sang Hyub Lee
  • Ji Won Yoo
  • Joo Kyung Park
  • Yong-Tae Kim
  • Jin-Young Jang
  • Sun-Whe Kim
  • Gyeong Hoon Kang
  • Yong Bum Yoon
Original Paper Gastrointestinal Oncology



Ampullary carcinoma is often considered to have a better prognosis than distal extrahepatic cholangiocarcinoma. However, studies that directly compare the recurrence and histopathological features between the two groups are rare.


Clinicopathologic factors and the long-term outcomes of 163 patients with ampullary carcinoma after radical resection were retrospectively evaluated and compared with those of 91 patients with distal extrahepatic cholangiocarcinoma.


Among the 163 ampullary carcinomas, T1 stage, well-differentiated tumors and perineural invasion were 45 (28%), 73 (45%), and 23 (14%), respectively, whereas, only five (6%) were T1 stage, 15 (17%) were well differentiated, and 63 (69%) showed perineural invasion (p < 0.001, for all) in distal extrahepatic cholangiocarcinomas. More patients with distal extrahepatic cholangiocarcinoma had liver metastasis than ampullary carcinoma (24% vs. 10%, p = 0.004). Multivariate analysis identified venous invasion and perineural invasion as risk factors for recurrence of ampullary carcinoma after radical resection. Only lymph node involvement was identified as a risk factor for recurrence of distal extrahepatic cholangiocarcinoma by multivariate analysis. Overall five-year survival of patients with ampullary cancer was higher than that of patients with distal extrahepatic cholangiocarcinoma (68% vs. 54%; p = 0.033). In patients without lymph node metastasis, a significant difference in survival was also observed between the two groups (p = 0.049).


Earlier diagnosis and the less frequent occurrence of pathological factors associated with tumor invasiveness in ampullary carcinoma than in distal extrahepatic cholangiocarcinoma may explain its association with a better prognosis.


Ampulla of Vater Cholangiocarcinoma Pancreaticoduodenectomy Prognosis Recurrence 



This study was supported in part by the Seoul National University Hospital research fund (grant no. 04-2005-010).


  1. 1.
    Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226(3):248–57PubMedCrossRefGoogle Scholar
  2. 2.
    Bouvet M, Gamagami RA, Gilpin EA, et al. Factors influencing survival after resection for periampullary neoplasms. Am J Surg 2000;180(1):13–7PubMedCrossRefGoogle Scholar
  3. 3.
    Stephens J, Kuhn J, O’Brien J, et al. Surgical morbidity, mortality, and long-term survival in patients with peripancreatic cancer following pancreaticoduodenectomy. Am J Surg 1997;174(6):600–3PubMedCrossRefGoogle Scholar
  4. 4.
    Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg 2003; 138(9):941–8PubMedCrossRefGoogle Scholar
  5. 5.
    Bottger TC, Boddin J, Heintz A, Junginger T. Clinicopathologic study for the assessment of resection for ampullary carcinoma. World J Surg 1997; 21(4):379–83PubMedCrossRefGoogle Scholar
  6. 6.
    Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology 2004; 51(60):1612–8PubMedGoogle Scholar
  7. 7.
    Yoshida T, Matsumoto T, Sasaki A, et al. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002; 137(1):69–73PubMedCrossRefGoogle Scholar
  8. 8.
    Sasaki R, Takahashi M, Funato O, et al. Prognostic significance of lymph node involvement in middle and distal bile duct cancer. Surgery 2001; 129(6):677–83PubMedCrossRefGoogle Scholar
  9. 9.
    Tompkins RK, Thomas D, Wile A, Longmire WP Jr. Prognostic factors in bile duct carcinoma: analysis of 96 cases. Ann Surg 1981; 194(4):447–57PubMedCrossRefGoogle Scholar
  10. 10.
    Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224(4):463–73PubMedCrossRefGoogle Scholar
  11. 11.
    Albores-Saavedra JHD, Klimstra DS. Tumors of the gallbladder, extrahepatic bile duct, and ampulla of Vater 3rd ed. Washington D.C., 2000Google Scholar
  12. 12.
    Bettschart V, Rahman MQ, Engelken FJ, et al. Presentation, treatment and outcome in patients with ampullary tumours. Br J Surg 2004; 91(12):1600–7PubMedCrossRefGoogle Scholar
  13. 13.
    Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg 1997; 225(5):590–9PubMedCrossRefGoogle Scholar
  14. 14.
    Beger HG, Thorab FC, Liu Z, et al. Pathogenesis and treatment of neoplastic diseases of the papilla of Vater: Kausch-Whipple procedure with lymph node dissection in cancer of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11(4):232–8PubMedCrossRefGoogle Scholar
  15. 15.
    Todoroki T, Koike N, Morishita Y, et al. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol 2003; 10(10):1176–83PubMedCrossRefGoogle Scholar
  16. 16.
    Balachandran P, Sikora SS, Kapoor S, et al. Long-term survival and recurrence patterns in ampullary cancer. Pancreas 2006; 32(4):390–5PubMedCrossRefGoogle Scholar
  17. 17.
    Howe JR, Klimstra DS, Moccia RD, et al. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998; 228(1):87–94PubMedCrossRefGoogle Scholar
  18. 18.
    Hsu HP, Yang TM, Hsieh YH, et al. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 2007; 14(1):50–60PubMedCrossRefGoogle Scholar
  19. 19.
    Lee JH, Whittington R, Williams NN, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 2000; 47(4):945–53PubMedCrossRefGoogle Scholar
  20. 20.
    Yoon YS, Kim SW, Park SJ, et al. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg 2005; 242(1):92–100PubMedCrossRefGoogle Scholar
  21. 21.
    Brown KM, Tompkins AJ, Yong S, et al. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg 2005; 140(6):529–32PubMedCrossRefGoogle Scholar
  22. 22.
    Yeo CJ, Sohn TA, Cameron JL, et al. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998; 227(6):821–31PubMedCrossRefGoogle Scholar
  23. 23.
    Kayahara M, Nagakawa T, Ohta T, et al. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 1999; 229(1):76–83PubMedCrossRefGoogle Scholar
  24. 24.
    Zerbi A, Balzano G, Leone BE, et al. Clinical presentation, diagnosis and survival of resected distal bile duct cancer. Dig Surg 1998; 15(5):410–6PubMedCrossRefGoogle Scholar
  25. 25.
    Murakami Y, Uemura K, Hayashidani Y, et al. pancreatoduodenectomy for distal cholangiocarcinoma: Prognostic impact of lymph node metastasis. World J Surg 2006; 31:337–42CrossRefGoogle Scholar
  26. 26.
    Murakami Y, Uemura K, Hayashidani Y, et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol 2007; 95(3):207–12PubMedCrossRefGoogle Scholar
  27. 27.
    Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234(4):507–17PubMedCrossRefGoogle Scholar
  28. 28.
    Sikora SS, Balachandran P, Dimri K, et al. Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol 2005; 31(2):158–63PubMedCrossRefGoogle Scholar
  29. 29.
    Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005; 103(1):111–8PubMedCrossRefGoogle Scholar
  30. 30.
    von Delius S, Lersch C, Schulte-Frohlinde E, et al. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005; 5(1):61CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Sang Myung Woo
    • 1
  • Ji Kon Ryu
    • 1
    • 4
  • Sang Hyub Lee
    • 1
  • Ji Won Yoo
    • 1
  • Joo Kyung Park
    • 1
  • Yong-Tae Kim
    • 1
  • Jin-Young Jang
    • 2
  • Sun-Whe Kim
    • 2
  • Gyeong Hoon Kang
    • 3
  • Yong Bum Yoon
    • 1
  1. 1.Department of Internal MedicineLiver Research Institute, Seoul National University College of MedicineJongno-guKorea (ROK)
  2. 2.Department of SurgerySeoul National University College of MedicineSeoulKorea
  3. 3.Department of PathologySeoul National University College of MedicineSeoulKorea
  4. 4.Department of Internal MedicineSeoul National University Hospital, Seoul National University College of MedicineJongno-guKorea

Personalised recommendations